ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

トリフルサール

Triflusal

HCID 9458
反応を作成
印刷
基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
322-79-2
標準SMILES
CC(=O)Oc1cc(C(F)(F)F)ccc1C(=O)O
InChIKey
RMWVZGDJPAKBDE-UHFFFAOYSA-N
分子式
C10H7F3O4
平均分子量
248.15 g/mol
単同位体質量
248.02964319

概要

2-acetyloxy-4-(trifluoromethyl)benzoic acid is a member of benzoic acids, a member of salicylates and a carboxylic ester.

名称と識別子

優先名称
Triflusal
IUPAC
2-acetyloxy-4-(trifluoromethyl)benzoic acid
現地名
トリフルサール
英語名
Triflusal
分子式
C10H7F3O4
分子量
248.16

名称と別名

Triflusal322-79-22-Acetoxy-4-trifluoromethylbenzoic acid2-(Acetyloxy)-4-(trifluoromethyl)benzoic acidTriflusalumDTXSID80453051Z0YFI05OODTXCID6025305RefChem:191611B01AC18206-297-5Disgren
名称をさらに表示
2-(アセチルオキシ)-4-(トリフルオロメチル)安息香酸トリフルサールジスグレン2-アセトキシ-4-(トリフルオロメチル)安息香酸アセチル-4-(トリフルオロメチル)サリチル酸ドリスゲン2-アセトキシ-4-トリフルオロメチル安息香酸トリフルサル4-(トリフルオロメチル)-2-アセトキシ安息香酸2-アセチルオキシ-4-(トリフルオロメチル)安息香酸ur1501DrisgenTriflusal-d3Triflusal CRSTriflusal (UR1501)TRIFLUOROTRIMESICACIDTriflusal, 10 mM in DMSO4-trifluoromethylsalicylicacidacetate
2-Acetoxy-4-(trifluoromethyl)benzoic Acid2-acetyloxy-4-(trifluoromethyl)benzoic acidAflenTriflusal [INN]MFCD00866793TrifluxBenzoic acid, 2-(acetyloxy)-4-(trifluoromethyl)-Prestwick1_000528

データベース識別子

CAS
322-79-2
PubChem CID
9458
DTXSID
DTXSID8045305
ChEMBL
CHEMBL1332032
ChEBI
CHEBI:94721
UNII
1Z0YFI05OO
EC Number
206-297-5
Nikkaji
J5.672C

物性

構造計算による物性

XLogP
2.1
極性表面積
63.6 Ų
水素結合供与体数
1
水素結合受容体数
7
回転可能結合数
3
重原子数
17
形式電荷
0
複雑度
313

実験および物理化学的性質

Drugs · 2 件

Pharmaceuticals -> Listed in ZINC15

Pharmaceuticals -> Blood and blood forming organs -> Antithrombotic agents

Solubility<1 mg/ml
Melting Point114-117ºC

物理化学的性質

融点
120 · 120-122° (upon slow heating); 110-112° (upon quick heating)
沸点
316 · 316.0±42.0 °C(Predicted)
比重(密度)
1.433 · 1.433±0.06 g/cm3(Predicted)
貯蔵温度
2 · Sealed in dry,2-8°C
溶解性
30 mg/mL · DMSO:>30mg/mL
酸解離定数(Pka)
2.97 · 2.97±0.10(Predicted)
外見
粉
色
ホワイトからオフホワイト
Merck
14 · 14,9688
InChI
1S/C10H7F3O4/c1-5(14)17-8-4-6(10(11,12)13)2-3-7(8)9(15)16/h2-4H,1H3,(H,15,16)
InChIKey
RMWVZGDJPAKBDE-UHFFFAOYSA-N
SMILES
FC(F)(F)c1cc(c(cc1)C(=O)O)OC(=O)C

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

GHS分類

GHS Classification · 4 件

Warning

H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]

P261, P264, P264+P265, P270, P271, P272, P280, P301+P317, P302+P352, P304+P340, P305+P351+P338, P319, P321, P330, P332+P317, P333+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 44 reports by companies from 6 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

危険有害性情報

Hazard Classes and CategoriesAcute Tox. 4 (100%)

安全データ

wgk
3
rtecs
GP4250000
hs_code
2918.29.7500
risk_code
22-36/37/38-43
hazard_code
Xn
safety_code
26-36/37
Hazard Classifications
Acute Tox. 4 OralEye Irrit. 2Skin Irrit. 2Skin Sens. 1STOT SE 3
ストレージクラス
11 - Combustible Solids

化学と産業

薬理情報

ATC Code · 2 件

B - Blood and blood forming organs

QB - Blood and blood forming organs

Protein BindingTriflusal binds almost completely to plasma proteins reaching a 99% of the administered dose.
Pharmacodynamics · 1 件

Triflusal is an antithrombotic anticoagulant. It irreversibly inhibits the production of thromboxane-B2 in platelets by acetylating cycloxygenase-1. Triflusal affects many other targets such as NF kappa B, which is a gene expression regulatory factor for cycloxygenase-a and cytokines. Numerous studies comparing the efficacy and safety profile (i.e. systemic hemorrhage) between triflusal and acetylsalsylic acid has shown either no significant difference or a better effacy and safety profile for triflusal. Triflusal has been shown to protect cerebral tissue due to its inhibition of lipid peroxidation resulting from anoxia-reoxygenation.

Mechanism of Action · 1 件

Triflusal is chemically related to acetylsalicylic acid (ASA) and irreversibly inhibits cycloxygenase-1 (COX-1) in platelets. Acetylation of the active group of COX-1 prevents the formation of thromboxane-B2 in platelets. However, it is unique because it spares the arachidonic acid metabolic pathway in endothelial cells. In addition, it favors the production of nitric oxide, a vasodilator.

Biological Half-LifeIn the healthy human, the half-life is 0.5 +/- 0.1h, while that of HTB is 34.3 +/- 5.3h.
Metabolism/MetabolitesIn the liver, triflusal undergoes deacetylation, forming its main metabolite 2-OH-4-trifluoromethyl benzoic acid (HTB). This major metabolite seems to have marked antiplatelet properties in vitro.
MeSH Pharmacological Classification · 1 件

Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.

関連反応

2 件
反応記録を作成
HRID 98027 の反応式
HRID 98027反応物として
HRID 1038770 の反応式
HRID 1038770反応物として

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
CAS データベース
322 · 322-79-2(CAS DataBase Reference)

化学的性質

化学的特性White to Off-White Solid

Absorption, Distribution and Excretion · 4 件

Absorbed in the small intestine with a bioavailability range from 83% to 100%. There is no significant difference between the absorption of the oral solution and capsule formulation. Triflusal displays a Cmax of 11.6 mcg/ml and a tmax of 0.88 h. The major metabolite of triflusal presents different pharmacokinetic properties by showing a Cmax and tmax of 92.7 mcg/ml and 4.96 h, respectively.

The elimination pathway of triflusal is primarily renal. Urine analysis has shown the presence of unchanged triflusal, HTB and the glycine conjugate of HTB.

The reported volume of distribution for triflusal is of 34L.

Renal clearance is 0.8 +/- 0.2L/h and 0.18 +/1 0.04L/h for triflusal and HTB, respectively.

応用分野

使用An analog of Aspirin; inhibits platelet aggregation. Antithrombotic.

上流・下流製品情報

下流製品

酢酸イオン4-(トリフルオロメチル)サリチル酸